There was only one KRAS-mutant tumor with mutations in both TP53 and STK11 or KEAP1. Excluding this single sample, we divided KRAS-mutant tumors into three groups: those with TP53 mutations (n = 20), those with STK11 and/or KEAP1 mutations (n = 25), and those without any of these mutations (n = 27). Here, STK11 is linked to neoplasm.